Overview

A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell Lung Cancer (NSCLC). Up to 180 patients will be randomized in a 1:1 ratio to one of the two treatment arms.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Erlotinib Hydrochloride